Third Quarter 2024 Results Key Financial Results Revenue: US$33.3m (up 48% ...

Even though Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO ) posted strong earnings recently, the stock hasn't reacted in ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $62.5, a high ...

The company has axed 80% of its staff and is considering a wind-down after the out-licencing deal of its lead antifungal was ...

Solventum, the healthcare company spun off from 3M earlier this year, has retained bankers to explore a sale of its ...

Q3 2024 Earnings Call Transcript November 5, 2024 Rhythm Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.73, expectations were $-0.8. Operator: Good day, and thank you for ...

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Sutro Biopharma (STRO – Research Report), with ...

*For more details about COVID-19 therapeutics and vaccines, diagnostic products and clinical trial delays, go to BioWorld Snapshots.

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Bruce, Professional Relations Associate, 3M Pharmaceuticals, personal communication, March 2007). Of interest to us were the four subjects (15%) with reactions to fragrance mix. The positive ...